Thursday 15 June 2017

The Brewery, London EC1

  • The 2017 European Mediscience Awards will take place on Thursday 15 June 2017
  • Nominations for the Awards are open - CLICK HERE TO NOMINATE



Consilium Strategic Communications Ltd
41 Lothbury
Tel: +44 (0) 20 3709 5700


Consilium Strategic Communications is an international advisory firm specialising in healthcare strategic communications. From offices in Europe and the US, Consilium's highly-skilled team provides long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes, investor relations and stakeholder challenges.


Phil Walker
Director Healthcare Corporate Finance
Tel: +44 (0) 203 829 5583

Dr Gary Waanders
Director Healthcare Research
Tel: +44 (0) 203 829 5617

Dominic Wilson
Director Healthcare Sales
Tel: +44 (0) 203 829 5618

Zeus Capital

Zeus Capital is an independent investment banking boutique, providing the highest quality advice to clients across a range of sectors and transactions. Our expertise enables us to guide companies through the often complex process of making acquisitions, selling a business, management buy outs/ins and IPOs. Zeus has helped raise over £2.7bn for clients in the last three years. In 2015 it raised 20% of funds for corporate IPOs on AIM. Zeus now acts as broker and/or financial adviser/nominated adviser to over 30 corporate clients with a combined market cap of £4.4bn. 

Zeus Capital’s Healthcare team has a wealth of experience managing transactions coupled with broking and research relationships that give a real insight into value drivers in the healthcare sector. The Healthcare team has advised on healthcare transactions raising a gross value of almost £300m since the beginning of 2014. Zeus Capital is proud to have 4D pharma, C4X Discovery, Motif Bio, Quantum Pharma and Oncimmune as its clients.


To contact one of our offices: 

Bavariaring 26
80336 München, Germany
Phone +49-89-210228-0

Kaiser-Friedrich-Ring 5
40545 Düsseldorf, Germany
Phone +49-211-529252-0

Or email us at:

MC Services AG 

MC Services AG is an international Public Relations and Investor Relations firm specialising in communications for the life sciences and healthcare sector. A complete team of science, finance, media and communication experts with relevant industry experience positions MC Services as the leading life sciences agency in Europe. MC Services’ long-standing clients include international public and private companies as well as venture capitalists and investment firms. Established for many years as a link between the healthcare industry and the financial markets, MC Services provides comprehensive services in the fields of Investor Relations, Public Relations and financial transactions. MC Services is based in Munich, Düsseldorf and London with partners in France and the United States.


Instinctif Partners provides a full service communications consultancy focused on science-based sectors.

65 Gresham Street
Tel: +44 (0) 20 7457 2020
Fax: +44 (0) 20 74866 7900

Instinctif Partners 

Instinctif Partners is an international business communications consultancy. Over three decades we have built a track record of delivering strategic counsel and insightful and creative programmes, focused on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Headquartered in London, our globally integrated and dedicated life sciences team serves clients around the world from our bases in the EU, USA and AsiaPacific.


If you would like more information, please contact one of our offices.

Tel: +31 (0) 20 550 4444

Tel: +44 20 7280 6850

Tel: +351 21 790 00 00

Tel: +33 1 49 27 10 00

Tel: +32 (0)2 509 12 11


Euronext is the primary exchange in the Euro zone with over 1,300 issuers worth €3.1tn in market capitalisation, an unmatched blue chip franchise consisting of 25 issuers in the EURO STOXX 50® benchmark and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise of running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market: in addition it offers EnterNext, which facilitates SMEs’ access to capital markets.

Over the last six years, Euronext has been the most active European stock exchange in the life science sector with 52 IPOs raising more than €1.3bn. This represents more than 50% of all IPOs (by deal number) by European life science companies including those that listed in the US.

In line with a broader effort to internationalise our markets, over the last two years Euronext life science franchise has grown beyond its historical borders, with four life science issuers from Ireland, Germany and the UK listing on Euronext since 2014. Two more life science companies, one from Germany and another from Switzerland, recently announced their intention to float on Euronext, highlighting international development of the Euronext life sciences franchise.


Shore Capital Markets, a division
of Shore Capital Group, is an independent securities business with a large and extensive research and sales capability offering comprehensive distribution to institutions and mid and small cap companies.

Bidhi Bhoma
Director, Investment
Banking - Healthcare
Tel: +44 (0)20 7468 7904

Dr Tara Raveendran
Healthcare Research
Tel: +44 (0)20 7647 8142

Shore Capital 

Shore Capital Markets, a division of Shore Capital Group, is an independent securities business with a large and extensive research and sales capability offering comprehensive distribution to institutions and mid and small cap companies. This distribution capability is complemented by Shore Capital’s experienced corporate finance and broking team who are dedicated to offering innovative and valued advice to London listed companies on both the Main Market and AIM. Shore Capital is also one of the largest market makers in the London market. Shore Capital Markets has been involved in transactions raising more than £3bn in equity capital markets since January 2014. 

Shore Capital’s Healthcare team provides comprehensive research coverage across the entire UK healthcare spectrum. This includes major pharma, speciality pharma, medical devices, life sciences and healthcare services. Our research product provides our clients with detailed insightful analysis with a particular focus on in-depth, high quality research. Healthcare research is distributed to over 300 UK and European institutions via our highly experienced sales people, including two healthcare specialists.


Panmure is a corporate and institutional stockbroker and investment bank with offices in the UK, Switzerland and Singapore.

Panmure Gordon & Co
One New Change
Tel: +44 (0)20 7886 2500 


Panmure Gordon

Panmure is a corporate and institutional stockbroker and investment bank with deep knowledge of the London markets. Our healthcare expertise has assisted clients to IPO, raise development capital and to complete successful M&A transactions. Our clients value our breadth of sector knowledge, track record and “can-do” client‑centric approach. 

Our ability to connect ideas with capital is enhanced by our international reach assisted by outstanding affiliations with Qatar’s largest investment bank, Qinvest, and India’s Ambit Capital.


Peel Hunt is an independent, full-service specialist broking and advisory house, focused on UK mid and small caps, with a leading Healthcare and Life Sciences franchise.

Moor House
120 London Wall
London EC2Y 5ET
Tel: +44 (0) 20 7418 8900
Fax: +44 (0) 20 7418 8848

Peel Hunt 

Peel Hunt is an independent, full-service specialist broking and advisory house with a focus on UK mid and small cap companies. Our partnership structure, 25 years of profitability, extensive trading platform and focus on long-term client relationships set us apart from our peers. We have expertise across a broad range of sectors and seek to offer high quality advice, ideas-led research and flawless execution within a team-based and collegiate environment. Peel Hunt benefits from a powerful distribution platform and since 2015 we have completed 70 ECM transactions (including 16 IPOs) with an aggregate transaction value of over £4bn. We have over 110 retained corporate clients and continue to grow strongly. 

Our Healthcare and Life Sciences team comprises dedicated sector specialists across research, sales and corporate with unparalleled access to small, mid and larger cap investors across the UK, Europe and North America. In recent years Peel Hunt has raised over £1bn for its healthcare clients and we represent companies in the sector with an aggregate market capitalisation of nearly £5bn.

Peel Hunt LLP is authorised and regulated by the Financial Conduct Authority.


60 Gresham Street, 4th Floor
London, EC2V 7BB

Tel: +44 (0) 20 3861 6625
Fax: +44 (0) 20 7600 5975

Northland Capital Partners Limited

Northland Capital is an independent institutional stockbroker and corporate adviser. The Company has a very strong track record in fundraising and advisory work across a number of industry sectors including natural resources, healthcare and biotech, TMT, consumer, and support services. 

Our team of highly motivated and experienced professionals are well connected and provide innovative ideas and solutions that enable our clients to fulfil their growth ambitions.

 Supported by: 



BioCentury Main Office
1235 Radio Road, Ste. 100
Redwood City, CA 94065-1217
Tel: +1 650-595-5333
Tel: +1 650-595-5589




Since 1993, BioCentury Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

BioCentury employs a fully integrated multimedia platform – including publications, online data solutions, conferences, and eLearning programs – to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.

The company publishes the weekly editions of its flagship publication, BioCentury®, and BioCentury Week in Review, plus daily editions of BioCentury Extra. BioCentury also publishes BioCentury Innovations, a weekly translational science journal.

The company also markets BCIQ, the industry's premiere business intelligence and research database. It provides easy access to data on thousands of companies and products and $400+ billion in financings.


LSP is one of the world's largest specialised healthcare and biotechnology investment firms.

Johannes Vermeerplein 9 
1071 DV Amsterdam 
Tel: +31 (0) 20 664 5500 
Fax: +31 (0) 20 676 8810

Life Sciences Partners 

With offices in Amsterdam, Munich and Boston, LSP has successfully invested in the healthcare and biotechnology sectors for over two decades. Since its inception in the late eighties, LSP has invested in a large number of both privately held and publicly traded life science companies, many of which have become leaders in their respective industries.


Cambridge (Head Office)
The Portway
Granta Park
CB21 6GS
Tel: +44 (0) 1223 896 450
Fax: +44 (0) 1223 896 471

One Nucleus 

One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe’s largest life science and healthcare cluster. We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers. 

One Nucleus’ mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients. 

Collectively the membership forms a commercial, clinical and academic powerhouse. Around 80% of our members are based in the Cambridge/London corridor, an area which is home to at least 60% of the UK’s life science industry base. 

With our critical mass of membership (being the largest in Europe by some way), as well as the services we offer, the member benefits include:

  • A large and significant pool of companies to support business to business interaction within the membership
  • Membership of a cluster of international size, relevance and visibility
  • Major impact both in the UK and overseas with the compelling excellence of our members articulated strongly to international organisations, institutions and Governments for ultimate member benefit